Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06516952 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 61 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting Enrollment target: estimated 330 to confirmed 349 · Study sites revised (120)v61 Show 2 more changesShow less
    • Enrollment target: estimated 330 to confirmed 349
    • Study sites revised (120)

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites revised (120)v60 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 121 to 120v59
  4. Study sites revised (121)v58 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 120 to 121v57
Show 45 earlier versionsHide 45 earlier versions
  1. Re-verified, no change to tracked fieldsv56
  2. Site details revised at 3 of 120 sitesv55
  3. Site details revised at 4 of 120 sitesv54
  4. Re-verified, no change to tracked fieldsv53
  5. Study sites revised (120)v52 See this version in full on ClinicalTrials.gov ↗
  6. Site details revised at 2 of 120 sitesv51
  7. Site details revised at 1 of 120 sitesv50
  8. Site details revised at 2 of 120 sitesv49
  9. Site details revised at 1 of 120 sitesv48
  10. Study sites: 121 to 120v47
  11. Site details revised at 1 of 121 sitesv46
  12. Site details revised at 1 of 121 sitesv45
  13. Study sites: 120 to 121v44
  14. Study sites: 145 to 120 Primary completion date: Oct 25, 2026 to Oct 19, 2026 · Completion date: Jun 2, 2027 to May 3, 2027v43 Show 2 more changesShow less
    • Primary completion date: Oct 25, 2026 to Oct 19, 2026
    • Completion date: Jun 2, 2027 to May 3, 2027
  15. Site details revised at 3 of 145 sitesv42
  16. Study sites: 144 to 145v41
  17. Site details revised at 1 of 144 sitesv40
  18. Study sites: 143 to 144v39
  19. Study sites: 141 to 143v38
  20. Re-verified, no change to tracked fieldsv37
  21. Study sites revised (141)v36 See this version in full on ClinicalTrials.gov ↗
  22. Study sites: 142 to 141v35
  23. Study sites: 137 to 142v34
  24. Re-verified, no change to tracked fieldsv33
  25. Study sites: 136 to 137v32
  26. Study sites: 135 to 136v31
  27. Study sites: 136 to 135v30
  28. Site details revised at 3 of 136 sitesv29
  29. Site details revised at 2 of 136 sitesv28
  30. Site details revised at 5 of 136 sitesv27
  31. Site details revised at 4 of 136 sitesv26
  32. Site details revised at 6 of 136 sitesv25
  33. Site details revised at 1 of 136 sitesv24
  34. Site details revised at 2 of 136 sitesv23
  35. Site details revised at 6 of 136 sitesv22
  36. Site details revised at 4 of 136 sitesv21
  37. Site details revised at 8 of 136 sitesv20
  38. Site details revised at 6 of 136 sitesv19
  39. Study sites: 135 to 136v18
  40. Study sites revised (135)v17 See this version in full on ClinicalTrials.gov ↗
  41. Site details revised at 5 of 135 sitesv16
  42. Site details revised at 4 of 135 sites Study title expanded, about 1 wordv15 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  43. Site details revised at 4 of 135 sitesv14
  44. Study sites revised (135)v13 See this version in full on ClinicalTrials.gov ↗
  45. Site details revised at 1 of 135 sitesv12
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Trial Details
NCT Number NCT06516952
Lead Sponsor Incyte Corporation
Conditions Prurigo Nodularis
Enrollment 349 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov